Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

3 Vaccine Stocks To Buy Now

By MarketBeat.com (Sean Sechler )Stock MarketsJul 21, 2021 05:21AM ET
www.investing.com/analysis/3-vaccine-stocks-to-buy-now-200592668
3 Vaccine Stocks To Buy Now
By MarketBeat.com (Sean Sechler )   |  Jul 21, 2021 05:21AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Just when investors started to think that COVID-19 headlines no longer make a big impact on equities, news related to the spread of the Delta variant of the virus hit the market with a vengeance. With concerns that the spread of this new variant could impact the economic rebound and more lockdowns going into effect all over the world, it’s clear that the market is still not immune to pandemic headline risk.

Naturally, vaccine stocks have been rallying on these headlines and could be in for more upside going forward as the world tries to stop the spread of these new variants. Keep in mind that if the companies producing COVID-19 vaccines can protect the public against new variants of the virus, it could lead to additional revenue for them.

While Moderna (NASDAQ:MRNA) has been the king of vaccine stocks and is getting added to the S&P 500, there are other names that present a better risk-to-reward profile at this time.

Here are 3 vaccine stocks we're looking at now:

1. Pfizer

While Pfizer (NYSE:PFE) stock probably won’t go vertical as Moderna has over the last few trading sessions, it’s still a fantastic long-term investment to consider adding and is a lot less volatile, which is certainly an attractive quality.

As one of the world’s largest pharmaceutical companies, Pfizer has a diverse portfolio of established drugs in addition to its COVID-19 vaccine, which means that investors can rely on the company to deliver consistent earnings regardless of vaccine demand.

Pfizer is committed to delivering a billion doses of its COVID-19 vaccine by the end of 2021 and should generate $26 billion in vaccine revenue as a result. The new variants could also mean that people need repeat vaccinations in order to boost efficacy, which could keep demand steady for years.

What’s also nice about this stock is that it trades at a much lower forward P/E ratio than peers in the large-cap biopharmaceutical sector. Finally, the stock currently offers a 3.89% dividend yield that is supported by steady cash flows, which makes it a great option for income investors.

2. Novavax

Novavax (NASDAQ:NVAX) is a clinical-stage vaccine company that has hit a few snags trying to get its COVID-19 vaccine—NVX-CoV2373—through the global regulatory process. However, the company is planning to file for Emergency Use Authorizations in Q3 and could be one of the more underrated vaccine stocks to add at this time.

All signs point towards Novavax’s COVID-19 vaccine being effective, as it achieved 89.3% overall efficacy in a late-stage clinical trial that was conducted in the United Kingdom.

What’s interesting about Novavax’s vaccine candidate is that it relies on a protein adjuvant instead of the mRNA approach, which is easier to make and can be stored in a refrigerator.

The company already has agreements to manufacture and distribute 100 million doses of the vaccine in the United States along with up to 180 million doses in countries like the U.K., Canada, and Australia after it receives regulatory approval.

There’s also a lot to like about the company’s prospects with additional vaccine candidates for influenza and other infectious diseases. The bottom line here is that if you are interested in a vaccine stock that could have a huge move in the coming months, it might be worth adding shares of Novavax at this time.

3. Johnson & Johnson

Sure, there have been a few negative headlines surrounding Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine, but the reports of adverse events following the use of the company's vaccine are extremely rare.

In fact, the FDA has noted that there isn’t enough data to prove the company’s vaccine causes the rare Guillain-Barre syndrome and that about 12.8 million people have received the company’s vaccine with only 100 suspected cases of the adverse reaction being reported thus far.

Regardless of how you feel about the prospects of Johnson & Johnson’s COVID-19 vaccine, it’s still one of the premier pharmaceutical, medical device, and consumer health care products companies in the world.

The company saw its Q1 revenue increase by 7.9% year-over-year to $22.3 billion and could see even stronger earnings going forward as elective procedures rebound.

Johnson & Johnson also has several key drugs like Stalara, Darzalex, and Imbruvica along with a strong pipeline of new drugs that investors should find attractive.

Finally, the company’s dividend aristocrat status and 2.54% dividend yield absolutely make it one of the best vaccine stocks to buy now.

Original Post

3 Vaccine Stocks To Buy Now
 

Related Articles

3 Vaccine Stocks To Buy Now

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
William Hineser
William Hineser Aug 04, 2021 11:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nvax is the key to the controversy.
Warren Buff
WBFT Jul 22, 2021 10:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very surprising that author of this article does not know BioNTech-BNTX. In his article, he is writing about Pfizer but even not one word about BNTX. Quite suspicious.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email